Vanda Pharmaceuticals Inc. Q4 2025 Earnings Call Summary

Revenue Growth - Fanapt revenue growth of 24% was primarily driven by a 149% surge in new-to-brand prescriptions following the bipolar disorder commercial launch [1] - Management attributes accelerating Fanapt momentum to targeted commercial investments, including direct-to-consumer campaigns and a sales force expansion to approximately 300 representatives [1] Product Performance - HETLIOZ revenue declined 7% due to generic competition, though the product has retained the majority of market share after three years of generic entry [1] - The approval of Nereus for motion sickness addresses a significant unmet need for the estimated 25% to 30% of U.S. adults experiencing symptoms during travel [1] - Strategic positioning of PONVORY is shifting toward psoriasis and ulcerative colitis to leverage its rapid lymphocyte recovery profile over competing S1P modulators [1] Financial Impact - The company recorded a one-time non-cash income tax charge of $113.7 million related to a valuation allowance against deferred tax assets based on projected pretax income [1]